Erudio Healtherudio.com
Drug
Apalutamide trials: what clinicians said in public
HCP commentary reports on 4 clinical trials studying apalutamide: LIBERTAS, NRG-GU008, PRIMORDIUM and VA STARPORT. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 13 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| LIBERTAS NCT05884398 · Janssen Research & Development, LLC | metastatic castration-sensitive prostate cancer | Phase 3 | 898 | 55 | Deep | Nov 17, 2026 | Preview |
| NRG-GU008 NCT04134260 · NRG Oncology | node-positive prostate cancer after radical prostatectomy | Phase 3 | 304 | 29 | Deep | Nov 15, 2026 | Preview |
| PRIMORDIUM NCT04557059 · Janssen Pharmaceutica N.V., Belgium | high-risk hormone-sensitive prostate cancer | Phase 3 | 312 | 19 | Deep | Nov 1, 2026 | Preview |
| VA STARPORT NCT04787744 · VA Office of Research and Development | oligometastatic prostate cancer | Phase 2/Phase 3 | 119 | 25 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| FORMULA-509 NCT03141671 · Dana-Farber Cancer Institute DeepView → | prostate cancer with rising PSA after radical prostatectomy | Phase 2 | Deep | View | |||
| TRIPLE-SWITCH NCT06592924 · Canadian Cancer Trials Group DeepView → | metastatic castration-sensitive prostate cancer with suboptimal PSA response | Phase 3 | Deep | View | |||
| NRG-GU006 NCT03371719 · NRG Oncology DeepView → | recurrent prostate cancer | Phase 2 | Deep | View | |||
| GUNS NCT04812366 · University of British Columbia DeepView → | high-risk localized prostate cancer | Phase 2 | Deep | View | |||
| PREDICT-RT NCT04513717 · NRG Oncology DeepView → | high risk prostate cancer | Phase 3 | Deep | View | |||
| PRESTO NCT03009981 · Alliance Foundation Trials, LLC. StandardView → | high-risk biochemically relapsed castration-sensitive prostate cancer | Phase 3 | Standard | View | |||
| LACOG 0415 NCT02867020 · Latin American Cooperative Oncology Group StandardView → | advanced prostate cancer with non-castrate testosterone levels | Phase 2 | Standard | View | |||
| PROTEUS NCT03767244 · Janssen Research & Development, LLC FocusedView → | high-risk localized or locally advanced prostate cancer | Phase 3 | Focused | View | |||
| TITAN NCT02489318 · Aragon Pharmaceuticals, Inc. FocusedView → | metastatic hormone-sensitive prostate cancer | Phase 3 | Focused | View | |||
| SPARTAN NCT01946204 · Aragon Pharmaceuticals, Inc. FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCT02703623 NCT02703623 · M.D. Anderson Cancer Center FocusedView → | metastatic castration-resistant prostate cancer | Phase 2 | Focused | View | |||
| NCT03298087 NCT03298087 · VA Office of Research and Development FocusedView → | newly diagnosed oligometastatic prostate cancer | Phase 2 | Focused | View | |||
| INDICATE NCT04423211 · ECOG-ACRIN Cancer Research Group FocusedView → | Not given | Phase 3 | Focused | View | |||